Glenmark Life Sciences IPO – Leveraging API Base Towards Contract Development, Manufacturing: Dolat Capital

Glenmark Life Sciences (a spin-off from Glenmark Pharmaceuticals Ltd.), operates in two segments – generic active pharmaceutical ingredients (91% of sales) and contract development and manufacturing …
( read original story …)

---